Evidence map›Paper›PMID 40571612›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation.

Kohei Takada, Noriaki Tachi, Takuto Shonai, Kota Kawasaki, Takehiro Sone, Hiraku Ogata, Shoichiro Kato, Shinichi Kobayashi, Fumihiko Kimura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kohei TakadaDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Noriaki TachiDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Takuto ShonaiDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Kota KawasakiDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Takehiro SoneDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Hiraku OgataDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Shoichiro KatoDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Shinichi KobayashiDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Fumihiko KimuraDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, various molecular targeted therapies have been developed for peripheral T-cell lymphoma (PTCL). However, relapsed/refractory (r/r) PTCL is associated with poor outcomes. Allogeneic stem cell transplantation (allo-SCT) can be effective against r/r PTCL owing to its graft-versus-lymphoma effect. Nevertheless, a posttransplant relapse is common. Although post-transplant preemptive therapy has shown favorable outcomes in leukemia, reports on its use for PTCL are extremely limited. We herein present the case of a patient with refractory PTCL who underwent allo-SCT followed by preemptive therapy with tucidinostat. The patient has maintained complete remission for 2-years. Thus, given its mechanism, tucidinostat may be a viable option for post-transplant therapy.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, T-Cell, PeripheralHumansMaleMiddle AgedTransplantation, HomologousTreatment Outcomehistone deacetylase inhibitorspost-transplantpreemptive therapyrelapsed/refractory peripheral T-cell lymphomatucidinostat

Identifiers

PMID40571612
PMCPMC12900584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.